Catalent Stock

Catalent EBIT

Delisted·Dec 17, 2024

The EBIT of Catalent (CTLT) as of Aug 5, 2026 is -749.00 M USD. In the previous year, EBIT was -156.00 M USD — a change of 380.13% (lower).

EBIT

-749.00 MUSD

YoY

380.13%

Last updated:

In 2026, Catalent's EBIT was -749.00 M USD, a 380.13% increase from the -156.00 M USD EBIT recorded in the previous year.

The Catalent EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B USD)
Date
EBIT (B USD)
Jan 1, 2023
-0.16 base
Jan 1, 2024
-0.75 base
Jan 1, 2025 (e)
0.24 base
Jan 1, 2026 (e)
0.26 base
Jan 1, 2027 (e)
0.29 base
Jan 1, 2028 (e)
1.20 base
Jan 1, 2029 (e)
0.00 base
Jan 1, 2030 (e)
0.00 base
YEAREBIT (B USD)
2030 est -
2029 est -
2028 est 1.20
2027 est 0.29
2026 est 0.26
2025 est 0.24
2024 -0.75
2023 -0.16
2022 0.73
2021 0.83
2020 0.14
2019 0.06
2018 0.27
2017 0.23
2016 0.22
2015 0.26
2014 0.24
2013 0.20
2012 0.20
2011 0.19
2010 0.17
2009 0.14
Access this data via the Eulerpool API

Catalent Revenue

Catalent Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
4.28 B USD
-156.00 M USD
-232.00 M USD
Jan 1, 2024
4.38 B USD
-749.00 M USD
-1.04 B USD
Jan 1, 2025 (e)
4.63 B USD
244.12 M USD
211.59 M USD
Jan 1, 2026 (e)
5.00 B USD
263.26 M USD
318.65 M USD
Jan 1, 2027 (e)
5.42 B USD
285.75 M USD
432.59 M USD
Jan 1, 2028 (e)
5.82 B USD
1.20 B USD
563.09 M USD
Jan 1, 2029 (e)
6.29 B USD
0.00 USD
708.94 M USD
Jan 1, 2030 (e)
6.83 B USD
0.00 USD
875.10 M USD

Catalent Margins

Catalent stock margins

The Catalent margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Catalent. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Catalent.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
24.79 %
-3.65 %
-5.43 %
Jan 1, 2024
21.75 %
-17.10 %
-23.81 %
Jan 1, 2025 (e)
21.75 %
5.27 %
4.57 %
Jan 1, 2026 (e)
21.75 %
5.27 %
6.38 %
Jan 1, 2027 (e)
21.75 %
5.27 %
7.99 %
Jan 1, 2028 (e)
21.75 %
20.64 %
9.68 %
Jan 1, 2029 (e)
21.75 %
0.00 %
11.27 %
Jan 1, 2030 (e)
21.75 %
0.00 %
12.82 %

Catalent Stock analysis

What does Catalent do? Catalent Inc is a global leader in advanced active ingredients and medical products, as well as solutions for drug development and manufacturing. The company was founded in 1933 by the Schering brothers in the USA and has become one of the preferred partners in the pharmaceutical industry due to its innovation, flexibility, and reliability. Catalent's business model is based on providing high-quality services and products that contribute to improving human health. The company offers a wide range of solutions, from active ingredient development to drug formulation and manufacturing, clinical trials, and product packaging. Through this comprehensive offering, Catalent helps its customers accelerate their drug development and product launch. The company is divided into different business sectors with specialized solutions, including the manufacturing of biopharmaceuticals such as antibodies, cell therapies, and vaccines, as well as medical devices, active ingredient manufacturing, and pharmaceutical development and manufacturing. Catalent's services also include active ingredient development, assisting customers in all stages of drug development from identifying new active ingredients to optimizing production processes. The company specializes in formulating drugs into suitable delivery forms that ensure safe and effective use, offering a variety of oral, inhalable, and parenteral formulations. Catalent also provides clinical trials, testing the efficacy and safety of drugs in clinical trials. The company has state-of-the-art facilities and expertise to professionally and successfully support its customers in conducting clinical studies. Additionally, Catalent offers a wide range of packaging solutions, including glass bottles, plastic containers, aluminum tubes, and the finishing and packaging of finished drugs. The company has advanced production systems that enable quick and flexible packaging production in any desired size and shape. Overall, Catalent provides its customers with a comprehensive range of services and products that enable fast and effective drug development and market launch. The company's strong innovation and diverse range of expertise make it a preferred partner in the pharmaceutical industry. Catalent is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Catalent's EBIT

Catalent's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Catalent's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Catalent's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Catalent’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Catalent stock

EBIT of Catalent is -749.00 M USD in 2026.

EBIT of Catalent changed from -156.00 M USD to -749.00 M USD, representing a 380.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Catalent since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Catalent historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Catalent

All Key Metrics — Catalent